Glucocorticoid receptor and Beta-2 adrenergic receptor (GR/β2-AR)

The Glucocorticoid Receptor (GR) and Beta-2 Adrenergic Receptor (β2-AR) are distinct proteins that function as a synergistic therapeutic target pair in respiratory medicine [PubMed: 23531485]. The GR (encoded by NR3C1) is a ligand-activated transcription factor that mediates the anti-inflammatory effects of corticosteroids by binding to glucocorticoid response elements (GREs) and inhibiting pro-inflammatory transcription factors like NF-κB [UniProt: P04150]. The β2-AR (encoded by ADRB2) is a G protein-coupled receptor that, upon activation by agonists, stimulates adenylyl cyclase to increase intracellular cAMP, leading to airway smooth muscle relaxation and bronchodilation [UniProt: P07550]. The combination of these targets is highly effective because of molecular crosstalk: corticosteroids increase β2-AR expression and prevent its desensitization, while β2-agonists can enhance GR nuclear translocation and DNA binding [PubMed: 20519449]. This dual targeting is the standard of care for managing asthma and chronic obstructive pulmonary disease (COPD), typically delivered via inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combinations [NIH: StatPearls - Asthma].

Other names

NR3C1ADRB2Glucocorticoid receptorBeta-2 adrenoceptorBeta-2 adrenergic receptorICS/LABA target complex

Drugs targeting this pair utilize a dual mechanism: the corticosteroid component binds to the GR to suppress airway inflammation and mucus production, while the beta-2 agonist component binds to the β2-AR to induce rapid or sustained bronchodilation. Synergistic effects occur as GR activation upregulates ADRB2 gene expression, and β2-AR signaling facilitates GR phosphorylation and nuclear localization [PubMed: 15191917, PubMed: 20519449].